Cadchem Laboratories Ltd

Cadchem Laboratories is an API manufacturing company holding Korean MFDS and WHO-GMP approvals, with a focus on cardiovascular, neurological and anti-diabetic segments for global markets. The company holds CEPs for clopidogrel bisulphate Form II and levetiracetam, with additional CEP filings planned for rosuvastatin calcium, rifaximin and brivaracetam, alongside current manufacturing of citicoline sodium, benfotiamine and rivaroxaban, and future plans for ticagrelor, quetiapine, apixaban, empagliflozin, dapagliflozin and ketorolac tromethamine.